
An anti-TIGIT antibody that engages with the immune system in multiple ways.
At iTeos we are pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics.
The ATP-adenosine pathway is recognized as a key pathway that modulates immune responses in pathological conditions. We designed Inupadenant to inhibit the ATP-adenosine pathway by specifically targeting A2AR, which is the primary adenosine receptor on immune cells with a high affinity for adenosine.
Our differentiated development approach is driven by biologic rationale and clinical need utilizing our IO candidates in intra-portfolio combinations and with programs of external collaborators.
Latest press releases
iTeos Reports First Quarter 2023 Financial Results and Provides Business Updates
– Belrestotug, formerly EOS-448, is advancing through multiple late-stage clinical trials including both doublet and triplet regimens – First-in-class program targeting a new…
iTeos Reports Fourth Quarter and Full Year 2022 Financial Results and Provide…
– 10 ongoing or planned clinical trials throughout 2023 to advance both differentiated clinical programs, anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and…